UNSPSC 51332510: Lenperone

This classification denotes an antipsychotic agent with the molecular formula C22H23F2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 13P4GX22ES chemically known as 1-butanone, 4-(4-(4-fluorobenzoyl)-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as lenperone, which bears US NIH Compound Identifier 32593. European Medicines Agency schedules Lenperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08434MIG.

UNSPSC 51332510 Lenperone is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter medications for community health, emergency response, and pharmacy benefit programs. The scope covers both standalone emergency-response pharmaceuticals and broader pharmacy supply contracts serving public health departments, healthcare commissions, and cooperative purchasing alliances that distribute products across multiple jurisdictions.

State and local issuers include county health departments, state health and human services commissions, and multi-state cooperative purchasing organizations. Seminole County, Florida, and the Texas Health and Human Services Commission represent recent buyers; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, manages contracts serving participating state and local facilities across multiple states including Oregon. Recent activity spans Florida, Texas, and the Upper Midwest through MMCAP's network. Representative recent opportunities include Seminole County's IFB60459723LAS, an IFB posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, soliciting vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across Oregon and Minnesota, posted January 20, 2026, with responses due March 26, 2026, requiring vendors to supply through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance.